Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by Benchmark

Benchmark restated their speculative buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a report published on Tuesday morning, Benzinga reports. They currently have a $17.00 target price on the stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $20.00 price target on shares of Reviva Pharmaceuticals in a research report on Monday, March 25th.

Reviva Pharmaceuticals Stock Down 5.6 %

NASDAQ:RVPH opened at $3.02 on Tuesday. The firm has a market capitalization of $84.32 million, a price-to-earnings ratio of -1.84 and a beta of -0.02. Reviva Pharmaceuticals has a twelve month low of $2.67 and a twelve month high of $9.25. The stock’s 50 day moving average price is $3.69 and its two-hundred day moving average price is $4.17.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Armistice Capital LLC increased its holdings in shares of Reviva Pharmaceuticals by 194.0% during the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after acquiring an additional 1,164,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Reviva Pharmaceuticals by 58.3% during the 4th quarter. Vanguard Group Inc. now owns 974,982 shares of the company’s stock worth $5,021,000 after acquiring an additional 359,050 shares during the last quarter. Colony Group LLC increased its holdings in shares of Reviva Pharmaceuticals by 66.7% during the 2nd quarter. Colony Group LLC now owns 155,000 shares of the company’s stock worth $908,000 after acquiring an additional 62,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Reviva Pharmaceuticals by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 150,949 shares of the company’s stock worth $885,000 after acquiring an additional 5,519 shares during the last quarter. Finally, EMC Capital Management increased its holdings in shares of Reviva Pharmaceuticals by 1,294.3% during the 3rd quarter. EMC Capital Management now owns 123,915 shares of the company’s stock worth $613,000 after acquiring an additional 115,028 shares during the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.